PIPELINE

RGN-259

  • Neurotrophic Keratitis
  • Dry Eye Disease

What is Neurotrophic Keratitis?

Neurotrophic keratitis is a degenerative disease characterized by reduced corneal sensation and poor corneal healing. The decrease or loss of corneal sensation and damage to corneal epithelial cells can cause ulcers, infections, melting, and perforation.

Surgical procedures, such as sealing the upper and lower eyelids to prevent emergencies and rapid infection during the onset of this rare disease, are the only available therapeutic options.

Conjunctival flap, Therapeutic contact lens Keratoplasty,
Amniotic membrane transplantation

Development Stage
Pipeline Treatment Areas Indication
Initial
Development
Clinical Trial
Phase 1
Clinical Trial
Phase 2
Clinical Trial
Phase 3
RGN-259
Ophthalmic desease
Neurotrophic Keratopathy
  • RGN-259 : An ophthalmic solution containing Thymosin Beta 4 (timbetasin) for ocular diseases
  • Through our U.S.-based joint venture (ReGenTree, LLC), we have completed the first Phase 3 trial (SEER-1) for the neurotrophic keratitis treatment (RGN-259) and are currently conducting additional Phase 3 trials (SEER-2 & SEER-3).
  • Designated as an Orphan Drug by the U.S. FDA for the development of the neurotrophic keratitis treatment.
임상관련정보
SEER-2(Phase 3)
VIEW MORE
SEER-3(Phase 3)
VIEW MORE
SEER-1 (Phase 3)
VIEW MORE
Clinical Research Paper
VIEW MORE
Wound Healing Research
VIEW MORE
Cell Migration Enhancement Research
VIEW MORE
NK (Neurotrophic Keratopathy)

SEER (Safety and Efficacy Examination of RGN-259)